Logo image of DC4.DE

DEXCOM INC (DC4.DE) Stock Fundamental Analysis

Europe - FRA:DC4 - US2521311074 - Common Stock

61.38 EUR
+0.63 (+1.04%)
Last: 10/24/2025, 7:00:00 PM
Fundamental Rating

6

Taking everything into account, DC4 scores 6 out of 10 in our fundamental rating. DC4 was compared to 59 industry peers in the Health Care Equipment & Supplies industry. DC4 scores excellent on profitability, but there are some minor concerns on its financial health. DC4 is valued quite expensively, but it does show have an excellent growth rating. This makes DC4 very considerable for growth investing!


Dividend Valuation Growth Profitability Health

8

1. Profitability

1.1 Basic Checks

DC4 had positive earnings in the past year.
In the past year DC4 had a positive cash flow from operations.
Each year in the past 5 years DC4 has been profitable.
DC4 had a positive operating cash flow in each of the past 5 years.
DC4.DE Yearly Net Income VS EBIT VS OCF VS FCFDC4.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M 800M

1.2 Ratios

DC4's Return On Assets of 7.80% is fine compared to the rest of the industry. DC4 outperforms 79.66% of its industry peers.
The Return On Equity of DC4 (22.21%) is better than 91.53% of its industry peers.
DC4's Return On Invested Capital of 14.52% is amongst the best of the industry. DC4 outperforms 94.92% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for DC4 is above the industry average of 9.04%.
The 3 year average ROIC (11.25%) for DC4 is below the current ROIC(14.52%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 7.8%
ROE 22.21%
ROIC 14.52%
ROA(3y)7.95%
ROA(5y)8.21%
ROE(3y)23.2%
ROE(5y)22.06%
ROIC(3y)11.25%
ROIC(5y)9.23%
DC4.DE Yearly ROA, ROE, ROICDC4.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 20 -20 30

1.3 Margins

DC4 has a Profit Margin of 13.29%. This is in the better half of the industry: DC4 outperforms 76.27% of its industry peers.
DC4's Profit Margin has improved in the last couple of years.
DC4's Operating Margin of 17.22% is fine compared to the rest of the industry. DC4 outperforms 76.27% of its industry peers.
In the last couple of years the Operating Margin of DC4 has grown nicely.
The Gross Margin of DC4 (60.01%) is comparable to the rest of the industry.
DC4's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 17.22%
PM (TTM) 13.29%
GM 60.01%
OM growth 3Y10.52%
OM growth 5Y8.87%
PM growth 3Y17.27%
PM growth 5Y15.84%
GM growth 3Y-3.98%
GM growth 5Y-0.72%
DC4.DE Yearly Profit, Operating, Gross MarginsDC4.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 40 60

5

2. Health

2.1 Basic Checks

DC4 has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
DC4 has more shares outstanding than it did 1 year ago.
DC4 has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, DC4 has an improved debt to assets ratio.
DC4.DE Yearly Shares OutstandingDC4.DE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M
DC4.DE Yearly Total Debt VS Total AssetsDC4.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B

2.2 Solvency

DC4 has an Altman-Z score of 5.05. This indicates that DC4 is financially healthy and has little risk of bankruptcy at the moment.
DC4 has a better Altman-Z score (5.05) than 83.05% of its industry peers.
DC4 has a debt to FCF ratio of 4.38. This is a neutral value as DC4 would need 4.38 years to pay back of all of its debts.
Looking at the Debt to FCF ratio, with a value of 4.38, DC4 is in the better half of the industry, outperforming 61.02% of the companies in the same industry.
DC4 has a Debt/Equity ratio of 0.50. This is a neutral value indicating DC4 is somewhat dependend on debt financing.
DC4 has a worse Debt to Equity ratio (0.50) than 61.02% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.5
Debt/FCF 4.38
Altman-Z 5.05
ROIC/WACC1.84
WACC7.87%
DC4.DE Yearly LT Debt VS Equity VS FCFDC4.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

2.3 Liquidity

DC4 has a Current Ratio of 1.52. This is a normal value and indicates that DC4 is financially healthy and should not expect problems in meeting its short term obligations.
DC4 has a Current ratio (1.52) which is in line with its industry peers.
A Quick Ratio of 1.35 indicates that DC4 should not have too much problems paying its short term obligations.
The Quick ratio of DC4 (1.35) is better than 66.10% of its industry peers.
Industry RankSector Rank
Current Ratio 1.52
Quick Ratio 1.35
DC4.DE Yearly Current Assets VS Current LiabilitesDC4.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B 4B

7

3. Growth

3.1 Past

The earnings per share for DC4 have decreased by -2.86% in the last year.
Measured over the past years, DC4 shows a very strong growth in Earnings Per Share. The EPS has been growing by 29.25% on average per year.
DC4 shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 9.30%.
Measured over the past years, DC4 shows a very strong growth in Revenue. The Revenue has been growing by 22.27% on average per year.
EPS 1Y (TTM)-2.86%
EPS 3Y35.38%
EPS 5Y29.25%
EPS Q2Q%11.63%
Revenue 1Y (TTM)9.3%
Revenue growth 3Y18.1%
Revenue growth 5Y22.27%
Sales Q2Q%15.21%

3.2 Future

DC4 is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 22.60% yearly.
The Revenue is expected to grow by 13.90% on average over the next years. This is quite good.
EPS Next Y26.84%
EPS Next 2Y26.2%
EPS Next 3Y24.65%
EPS Next 5Y22.6%
Revenue Next Year14.99%
Revenue Next 2Y15.17%
Revenue Next 3Y14.81%
Revenue Next 5Y13.9%

3.3 Evolution

The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
DC4.DE Yearly Revenue VS EstimatesDC4.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 2B 4B 6B 8B
DC4.DE Yearly EPS VS EstimatesDC4.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 1 2 3 4 5

3

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 41.76, the valuation of DC4 can be described as expensive.
DC4's Price/Earnings is on the same level as the industry average.
When comparing the Price/Earnings ratio of DC4 to the average of the S&P500 Index (26.91), we can say DC4 is valued expensively.
The Price/Forward Earnings ratio is 27.08, which means the current valuation is very expensive for DC4.
The rest of the industry has a similar Price/Forward Earnings ratio as DC4.
DC4's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 22.92.
Industry RankSector Rank
PE 41.76
Fwd PE 27.08
DC4.DE Price Earnings VS Forward Price EarningsDC4.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40

4.2 Price Multiples

62.71% of the companies in the same industry are cheaper than DC4, based on the Enterprise Value to EBITDA ratio.
The rest of the industry has a similar Price/Free Cash Flow ratio as DC4.
Industry RankSector Rank
P/FCF 48.89
EV/EBITDA 26.02
DC4.DE Per share dataDC4.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6 8

4.3 Compensation for Growth

DC4's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
The excellent profitability rating of DC4 may justify a higher PE ratio.
A more expensive valuation may be justified as DC4's earnings are expected to grow with 24.65% in the coming years.
PEG (NY)1.56
PEG (5Y)1.43
EPS Next 2Y26.2%
EPS Next 3Y24.65%

0

5. Dividend

5.1 Amount

No dividends for DC4!.
Industry RankSector Rank
Dividend Yield N/A

DEXCOM INC

FRA:DC4 (10/24/2025, 7:00:00 PM)

61.38

+0.63 (+1.04%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)07-30 2025-07-30/amc
Earnings (Next)10-30 2025-10-30/amc
Inst Owners97.73%
Inst Owner ChangeN/A
Ins Owners0.19%
Ins Owner ChangeN/A
Market Cap24.07B
Revenue(TTM)4.30B
Net Income(TTM)571.50M
Analysts84.57
Price Target89.5 (45.81%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.34%
Min EPS beat(2)-4.09%
Max EPS beat(2)6.77%
EPS beat(4)2
Avg EPS beat(4)-1.87%
Min EPS beat(4)-11.66%
Max EPS beat(4)6.77%
EPS beat(8)6
Avg EPS beat(8)9.43%
EPS beat(12)10
Avg EPS beat(12)14.38%
EPS beat(16)11
Avg EPS beat(16)8.49%
Revenue beat(2)1
Avg Revenue beat(2)0.34%
Min Revenue beat(2)-0.19%
Max Revenue beat(2)0.88%
Revenue beat(4)1
Avg Revenue beat(4)-0.54%
Min Revenue beat(4)-1.66%
Max Revenue beat(4)0.88%
Revenue beat(8)2
Avg Revenue beat(8)-0.78%
Revenue beat(12)5
Avg Revenue beat(12)-0.39%
Revenue beat(16)6
Avg Revenue beat(16)-0.42%
PT rev (1m)0%
PT rev (3m)0.76%
EPS NQ rev (1m)0.42%
EPS NQ rev (3m)0.28%
EPS NY rev (1m)0.14%
EPS NY rev (3m)1.07%
Revenue NQ rev (1m)0.08%
Revenue NQ rev (3m)0.67%
Revenue NY rev (1m)-0.02%
Revenue NY rev (3m)0.23%
Valuation
Industry RankSector Rank
PE 41.76
Fwd PE 27.08
P/S 6.49
P/FCF 48.89
P/OCF 28.25
P/B 10.84
P/tB 11.34
EV/EBITDA 26.02
EPS(TTM)1.47
EY2.39%
EPS(NY)2.27
Fwd EY3.69%
FCF(TTM)1.26
FCFY2.05%
OCF(TTM)2.17
OCFY3.54%
SpS9.46
BVpS5.66
TBVpS5.41
PEG (NY)1.56
PEG (5Y)1.43
Graham Number13.68
Profitability
Industry RankSector Rank
ROA 7.8%
ROE 22.21%
ROCE 18.43%
ROIC 14.52%
ROICexc 53.56%
ROICexgc 59.66%
OM 17.22%
PM (TTM) 13.29%
GM 60.01%
FCFM 13.27%
ROA(3y)7.95%
ROA(5y)8.21%
ROE(3y)23.2%
ROE(5y)22.06%
ROIC(3y)11.25%
ROIC(5y)9.23%
ROICexc(3y)35.45%
ROICexc(5y)29.66%
ROICexgc(3y)40.94%
ROICexgc(5y)33.19%
ROCE(3y)14.28%
ROCE(5y)11.73%
ROICexgc growth 3Y55.18%
ROICexgc growth 5Y18.96%
ROICexc growth 3Y50.14%
ROICexc growth 5Y16.58%
OM growth 3Y10.52%
OM growth 5Y8.87%
PM growth 3Y17.27%
PM growth 5Y15.84%
GM growth 3Y-3.98%
GM growth 5Y-0.72%
F-Score6
Asset Turnover0.59
Health
Industry RankSector Rank
Debt/Equity 0.5
Debt/FCF 4.38
Debt/EBITDA 1.33
Cap/Depr 176.58%
Cap/Sales 9.69%
Interest Coverage 250
Cash Conversion 101.12%
Profit Quality 99.88%
Current Ratio 1.52
Quick Ratio 1.35
Altman-Z 5.05
F-Score6
WACC7.87%
ROIC/WACC1.84
Cap/Depr(3y)175.34%
Cap/Depr(5y)240.83%
Cap/Sales(3y)9.32%
Cap/Sales(5y)10.84%
Profit Quality(3y)97.76%
Profit Quality(5y)73.64%
High Growth Momentum
Growth
EPS 1Y (TTM)-2.86%
EPS 3Y35.38%
EPS 5Y29.25%
EPS Q2Q%11.63%
EPS Next Y26.84%
EPS Next 2Y26.2%
EPS Next 3Y24.65%
EPS Next 5Y22.6%
Revenue 1Y (TTM)9.3%
Revenue growth 3Y18.1%
Revenue growth 5Y22.27%
Sales Q2Q%15.21%
Revenue Next Year14.99%
Revenue Next 2Y15.17%
Revenue Next 3Y14.81%
Revenue Next 5Y13.9%
EBIT growth 1Y6.1%
EBIT growth 3Y30.52%
EBIT growth 5Y33.11%
EBIT Next Year77.25%
EBIT Next 3Y38.83%
EBIT Next 5Y31.4%
FCF growth 1Y22.49%
FCF growth 3Y127.88%
FCF growth 5Y36.21%
OCF growth 1Y28.04%
OCF growth 3Y30.77%
OCF growth 5Y25.76%

DEXCOM INC / DC4.DE FAQ

What is the ChartMill fundamental rating of DEXCOM INC (DC4.DE) stock?

ChartMill assigns a fundamental rating of 6 / 10 to DC4.DE.


Can you provide the valuation status for DEXCOM INC?

ChartMill assigns a valuation rating of 3 / 10 to DEXCOM INC (DC4.DE). This can be considered as Overvalued.


Can you provide the profitability details for DEXCOM INC?

DEXCOM INC (DC4.DE) has a profitability rating of 8 / 10.


What is the earnings growth outlook for DEXCOM INC?

The Earnings per Share (EPS) of DEXCOM INC (DC4.DE) is expected to grow by 26.84% in the next year.